Establishment and operation of a good manufacturing practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease

British Journal of Haematology

Volumn 167, Issue 3, 2014, Pages 402-410

  Vickers, Mark A ^a,b   Wilkie, Gwen M ^a   Robinson, Nicolas ^a   Rivera, Nadja ^a   Haque, Tanzina ^c   Crawford, Dorothy H ^d   Barry, Jacqueline ^a   Fraser, Neil ^a   Turner, David M ^a   Robertson, Victoria ^a   Dyer, Phil ^a   Flanagan, Peter ^e   Newlands, Helen R ^a   Campbell, John ^a   Turner, Marc L ^a  

^a SCOTTISH NATIONAL BLOOD TRANSFUSION SERVICE   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e New Zealand Blood Service   (New Zealand)

Author keywords

Cell therapy; Cytotoxicity; Epstein Barr virus; Lymphoproliferative disease

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; BLOOD DONOR; CELL THERAPY; CELL TRANSPLANTATION; CERTIFICATION; CHILD; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; DONOR SELECTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; EUROPEAN; FEMALE; GOOD MANUFACTURING PRACTICE; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HEALTH CARE MANAGEMENT; HEALTH SERVICE; HLA MATCHING; HUMAN; LICENSING; LYMPHOPROLIFERATIVE DISEASE; MALE; MIDDLE AGED; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; REMISSION; UNRELATED DONORS; YOUNG ADULT; ADOPTIVE IMMUNOTHERAPY; ALLOGRAFT; CENTRAL NERVOUS SYSTEM NEOPLASMS; EPSTEIN-BARR VIRUS INFECTIONS; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INFANT; LEIOMYOSARCOMA; LUNG NEOPLASMS; LYMPHOPROLIFERATIVE DISORDERS; NEW ZEALAND; ORGANIZATION AND MANAGEMENT; POSTOPERATIVE COMPLICATIONS; PRESCHOOL CHILD; SARCOMA; STANDARDS; TRANSPLANTATION; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ALLOGRAFTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFANT; LEIOMYOSARCOMA; LICENSURE; LUNG NEOPLASMS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEW ZEALAND; POSTOPERATIVE COMPLICATIONS; REMISSION INDUCTION; SARCOMA; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; TISSUE BANKS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84912035006     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13051     Document Type: Article

References (36)

1. Abu-Elmagd, K.M., Mazariegos, G., Costa, G., Soltys, K., Bond, G., Sindhi, R., Green, M., Jaffe, R., Wu, T., Koritsky, D., Matarese, L., Schuster, B., Martin, L., Dvorchik, I. & Nalesnik, M.A. (2009) Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: improved outcomes with new outlooks. Transplantation, 88, 926-934.
2. Almohmeed, Y.H., Avenell, A., Aucott, L. & Vickers, M.A. (2013) Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. PLoS One, 8, e61110.
3. Barker, J.N., Doubrovina, E., Sauter, C., Jaroscak, J.J., Perales, M.A., Doubrovina, M., Prockop, S.E., Koehne, G. & O'Reilly, R.J. (2010) Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third party EBV-specific cytotoxic T lymphocytes. Blood, 116, 5045-5049.
4. Berghuis, D., de Hooge, A.S., Santos, S.J., Horst, D., Wiertz, E.J., van Eggermond, M.C., van den Elsen, P.J., Taminiau, A.H., Ottaviano, L., Schaefer, K.L., Dirksen, U., Hooijberg, E., Mulder, A., Melief, C.J., Egeler, R.M., Schilham, M.W., Jordanova, E.S., Hogendoorn, P.C. & Lankester, A.C. (2009) Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. The Journal of Pathology, 218, 222-231.
5. Bollard, C.M., Rooney, C.M. & Heslop, H.E. (2012) T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nature Reviews Clinical Oncology, 9, 510-519.
6. Bollard, C.M., Gottschalk, S., Torrano, V., Diouf, O., Ku, S., Hazrat, Y., Carrum, G., Ramos, C., Fayad, L., Shpall, E.J., Pro, B., Liu, H., Wu, M.F., Lee, D., Sheehan, A.M., Zu, Y., Gee, A.P., Brenner, M.K., Heslop, H.E. & Rooney, C.M. (2014) Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr Virus latent membrane proteins. Journal of Clinical Oncology, 32, 798-808.
7. Burns, D., Clesham, K., Haughton, J., Lannon, M., Hussein, H., Marsh, J., Lennard, A.L., Johnson, R.J., Cwynarksi, K. & Chaganti, S. (2013) Outcomes with rituximab monotherapy versus R-CHOP in post-transplant lymphoproliferative disease arising after solid organ transplant: a multicentre UK Study. Blood, 122, 3043.
8. Caillard, S., Porcher, R., Provot, F., Dantal, J., Choquet, S., Durrbach, A., Morelon, E., Moal, V., Janbon, B., Alamartine, E., Noble, C.P., Morel, D., Kamar, N., Buchler, M., Mamzer, M.F., Peraldi, M.N., Hiesse, C., Renoult, E., Toupance, O., Rerolle, J.P., Delmas, S., Lang, P., Lebranchu, Y., Heng, A.E., Rebibou, J.M., Mousson, C., Glotz, D., Rivalan, J., Thierry, A., Etienne, I., Moal, M.C., Albano, L., Subra, J.F., Ouali, N., Westeel, P.F., Delahousse, M., Genin, R., Hurault de Ligny, B. & Moulin, B. (2013) Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. Journal of Clinical Oncology, 31, 1302-1309.
9. Chen, J.N., He, D., Tang, F. & Shao, C.K. (2012) Epstein Barr virus-associated gastric carcinoma: a newly defined entity. Journal of Clinical Gastroenterology, 46, 262-271.
10. Cruz, C.R., Hanley, P.J., Liu, H., Torrano, V., Lin, Y.F., Arce, J.A., Gottschalk, S., Savoldo, B., Dotti, G., Louis, C.U., Leen, A.M., Gee, A.P., Rooney, C.M., Brenner, M.K., Bollard, C.M. & Heslop, H.E. (2010) Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy, 12, 743-749.
11. Derby, E., Reddy, V., Kopp, W., Nelson, E., Baselar, M., Sayers, T. & Malyguine, A. (2001) Three-color flow cytometric assay for the study of the mechanisms of cell-mediated cytotoxicity. Immunology Letters, 78, 35-39.
12. Dojcinov, S.D., Venkataraman, G., Pittaluga, S., Wlodarska, I., Schrager, J.A., Raffeld, M., Hills, R.K. & Jaffe, E.S. (2011) Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood, 117, 4726-4735.
13. Doubrovina, E., Oflaz-Sozmen, B., Prockop, S.E., Kernan, N.A., Abramson, S., Teruya-Feldstein, T., Hedvat, C., Chou, J.F., Heller, G., Barker, J.N., Boulad, F., Castro-Malaspina, H., George, D., Jakubowski, A., Koehne, G., Papadopoulos, E.P., Scaradavou, A., Small, T.N., Khalaf, R., Young, J.W. & O'Reilly, R.J. (2012) Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood, 119, 2644-2656.
14. Gerdemann, U., Katari, U.L., Papadopoulou, A., Keirnan, J.M., Craddock, J.A., Liu, H., Martinez, C.A., Kennedy-Nasser, A., Leung, K.S., Gottschalk, S.M., Krance, R.A., Brenner, M.K., Rooney, C.M., Heslop, H.E. & Leen, A.M. (2013) Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Molecular Therapy, 21, 2113-2121.
15. Hanlon, P., Avenell, A., Aucott, L. & Vickers, M.A. (2014) Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and systemic lupus erythematosus. Arthritis Research & Therapy, 16, R3. doi:10.1186/ar4429
16. Haque, T., Taylor, C., Wilkie, G.M., Murad, P., Amlot, P.L., Beath, S., McKiernan, P.J. & Crawford, D.H. (2001) Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation, 72, 1399-1402.
17. Haque, T., Wilkie, G.M., Taylor, C., Amlot, P.L., Murad, P., Iley, A., Dombagoda, D., Britton, K.M., Swerdlow, A.J. & Crawford, D.H. (2002) Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet, 360, 436-442.
18. Haque, T., Wilkie, G.M., Jones, M.M., Higgins, C.D., Urquhart, G., Wingate, P., Burns, D., McAulay, K., Turner, M., Bellamy, C., Amlot, P.L., Kelly, D., MacGilchrist, A., Gandhi, M.K., Swerdlow, A.J. & Crawford, D.H. (2007) Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood, 110, 1123-1131.
19. Haque, T., McAulay, K.A., Kelly, D. & Crawford, D.H. (2010) Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up. Transplantation, 90, 93-94.
20. Heslop, H.E. (2009) How I treat EBV lymphoproliferation. Blood, 114, 4002-4008.
21. Heslop, H.E., Slobod, K.S., Pule, M.A., Hale, G.A., Rousseau, A., Smith, C.A., Bollard, C.M., Liu, H., Wu, M.F., Rochester, R.J., Amrolia, P.J., Hurwitz, J.L., Brenner, M.K. & Rooney, C.M. (2010) Longterm outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 115, 925-935.
22. Hislop, A.D., Taylor, G.S., Sauce, D. & Rickinson, A.B. (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annual Review of Immunology, 25, 587-617.
23. Leen, A.M., Bollard, C.M., Mendizabal, A.M., Shpall, E.J., Szabolcs, P., Antin, J.H., Kapoor, N., Pai, S.Y., Rowley, S.D., Kebriaei, P., Dey, B.R., Grilley, B.J., Gee, A.P., Brenner, M.K., Rooney, C.M. & Heslop, H.E. (2013) Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood, 121, 5113-5123.
24. Long, H.M., Zuo, J., Leese, A.M., Gudgeon, N.H., Jia, H., Taylor, G.S. & Rickinson, A.B. (2009) CD4 + T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells. Blood, 114, 807-815.
25. Messahel, B., Taj, M.M., Hobson, R., Hadzic, N., Ramsay, A., Hann, I. & Pinkerton, R. (2006) Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: a United Kingdom Children's Cancer Study Group (UKCCSG) retrospective review. Leukemia and Lymphoma, 47, 2584-2589.
26. Moosmann, A., Bigalke, I., Tischer, J., Schirrmann, L., Kasten, J., Tippmer, S., Leeping, M., Prevalšek, D., Jaeger, G., Ledderose, G., Mautner, J., Hammerschmidt, W., Schendel, D.J. & Kolb, H.-J. (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood, 115, 2960-2970.
27. Ok, C.Y., Papathomas, T.G., Medeiros, L.J. & Young, K.H. (2013) EBV-positive diffuse large B cell lymphoma of the elderly. Blood, 122, 328-340.
28. Papadopoulos, E.B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M.H., Castro-Malaspina, H., Childs, B.H., Gillio, A.P., Small, T.N., Young, J.W., Kernan, N.A. & O'Reilly, R.J. (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New England Journal of Medicine, 330, 1185-1191.
29. Prockop, S.E., Doubrovina, E., Barker, J.N., Baroudy, K., Boulad, F., Khalaf, R., Kernan, N.A., Kobos, R., Papadopoulos, E.B., Scaradavou, A., Small, T.N., Wasilewski, G. & O'Reilly, R.J. (2012) Third party donor derived EBV specific T cells for the treatment of Refractory EBV-related malignancies in immunodeficient recipients. Blood, 120, 577.
30. Roschewski, M. & Wilson, W.H. (2012) EBV-associated lymphomas in adults. Best Practice & Research Clinical Haematology, 25, 75-89.
31. Styczynski, J., Gil, L., Tridello, G., Ljungman, P., Donnelly, J.P., van der Velden, W., Omar, H., Martino, R., Halkes, C., Faraci, M., Theunissen, K., Kalwak, K., Hubacek, P., Sica, S., Nozzoli, C., Fagioli, F., Matthes, S., Diaz, M.A., Migliavacca, M., Balduzzi, A., Tomaszewska, A., Camara, R.de.L., van Biezen, A., Hoek, J., Iacobelli, S., Einsele, H. & Cesaro, S.; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation (2013) Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clinical Infectious Diseases, 57, 794-802.
32. Sun, Q., Burton, R., Reddy, V. & Lucas, K.G. (2002) Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory RBV-related lymphoma. British Journal of Haematology, 118, 799-808.
33. Uhlin, M., Gertow, J., Uzunel, M., Okas, M., Berglund, S., Watz, E., Brune, M., Ljungman, P., Maeurer, M. & Mattsson, J. (2012) Rapid salvage treatment with virus-specific T-cells for therapy-resistant disease. Clinical Infectious Diseases, 55, 1064-1073.
34. Uhlin, M., Wikell, H., Sundin, M., Blennow, O., Maeurer, M., Ringden, O., Winiarski, J., Ljungman, P., Remberger, M. & Mattsson, J. (2014) Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica, 99, 346-352.
35. Visser, E., Milne, D., Collacott, I., McLernon, D., Counsell, C. & Vickers, M. (2014) Decreasing Incidence and Winter Peak of Infectious Mononucleosis in Northern Scotland. BMC Infectious Diseases, 14, 151.
36. Wilkie, G.M., Taylor, C., Jones, M.M., Burns, D.M., Turner, M., Kilpatrick, D., Amlot, P.L., Crawford, D.H. & Haque, T. (2004) Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. Journal of Immunotherapy, 27, 309-316.